Abstract
Lantibiotics are a group of ribosomally synthesised peptides that contain post-translational modifications consisting of (methyl)lanthionine residues forming bridges that confer them characteristic structures. Most lantibiotics are antibacterials that bind to the cell wall precursor lipid II. They can be rod shaped or globular depending on the distribution of the lanthionine residues. Their biosynthetic pathway is relatively simple when compared to other secondary metabolites. Due to this simplicity, genetic manipulation of the pathways is a very attractive tool to obtain variants that might have improved properties. Mutagenesis programmes have shown that the biosynthetic machinery of lantibiotics has relaxed specificity allowing the production of large collections of variants. Lantibiotic gene clusters are a common feature within bacteria, particularly Gram-positive organisms. Genome mining and in vitro synthesis experiments suggest that there is a great potential for discovery of new lantibiotics. With the increasing need for effective antibiotics against multidrug-resistant pathogens, lantibiotics are an attractive option for a new class of molecules. There are two lantibiotics in late preclinical development for use against systemic Gram-positive infections, one lantibiotic in Phase 1 clinical trials for the treatment of Clostridium difficile infections and another lantibiotic in Phase 2b for the treatment of cystic fibrosis. The potential of lantibiotics for the treatment of bacterial infections should become a reality in the next few years with the current compounds going through the corresponding drug development stages and new compounds joining the collection of useful compounds in the fight against multidrug-resistant bacteria.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allgaier H, Jung J, Werner RG, Schneider U, Zahner H (1986) Epidermin: sequencing of a heterodet tetracyclic 21-peptide amide antibiotic. Eur J Biochem 160:9–22
Altena K, Guder A, Cramer C, Bierbaum G (2000) Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl Env Microbiol 66:2565–2571
Appleyard AN, Ayala T, Boakes S, Cortes J, Dawson MJ, Choi S, Lightfoot A, Read D, Todd M, Wadman SN (2009a) NVB302: a narrow spectrum antibiotic under development for the treatment of Clostridium difficile infection. 49th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, Poster F1-1517
Appleyard AN, Candiani G, Carman R, Dawson MJ, Read D, Wadman SN (2009b) NVB302: gastrointestinal stability and in vivo activity in the hamster cecitis model for Clostridium difficile infection. 49th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, Poster F1-1520
Appleyard AN, Choi S, Read DM, Lightfoot A, Boakes S, Hoffmann A, Chopra I, Bierbaum G, Rudd BA, Dawson MJ, Cortes J (2009c) Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol 16:490–498
Begley M, Cotter PD, Hill C, Ross P (2009) Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for Lan M proteins. Appl Environ Microbiol 75:5451–5460
Boakes S, Cortes J, Appleyard AN, Rudd BA, Dawson MJ (2009) Organization of the genes encoding the biosynthesis of actagardine and engineering a variant generation system. Mol Microbiol 72:1126–1136
Boakes S, Appleyard AN, Cortes J, Dawson MJ (2010) Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362. J Antibiot 63:351–358
Brötz H, Bierbaum G, Leopold K, Reynolds P, Sahl HG (1998a) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 42:154–160
Brötz H, Josten M, Wiedemann I, Schneider U, Götz F, Bierbaum G, Sahl HG (1998b) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30:317–327
Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, Feroggio M, Ciciliato I, Corti E, Candiani G, Marinelli F, Selva E (2007) A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry 46:884–895
Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F (2008) Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 15:22–31
Chatterjee C, Paul M, Xie L, van der Donk WA (2005) Biosynthesis and mode of action of lantibiotics. Chem Rev 105:633–684
Chatterjee S, Chatterjee S, Lad SJ, Phansalkar MS, Rupp BN, Ganguli BN, Fehlhaber HW, Kogler H (1992) Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J Antibiot 45:832–838
Cotter PD, Deegan LH, Lawton EM, Draper LA, O’Connor PM, Hill C, Ross RP (2006) Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol 62:735–747
Dawson MJ (2006) The lantibiotics: an underexploited class of natural products with broad potential. Chem Today 24:25–27
Dawson MJ, Appleyard AN, Cortes-Bargallo J, Wadman SN (2011) Actagardine derivatives and pharmaceutical use thereof. WO 2011/095769
Delves-Broughton J (1990) Nisin and its uses as a food preservative. Food Technol 44:100–117
Dodd H, Gasson MJ, Mayer M, Narbad A (2006) Identifying lantibiotic gene clusters and novel lantibiotic genes. WO 2006/111743
Driessen AJ, van den Hooven HW, Kuiper W, van de Kamp M, Sahl HG, Konings RN, Konings WN (1995) Mechanistic studies of lantibiotic-induced permeabilization of phospholipid vesicles. Biochemistry 34:1606–1614
Field D, Collins B, Cotter PD, Hill C, Ross RP (2007) A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities. J Mol Microbiol Biotechnol 13:226–234
Field D, Connor PM, Cotter PD, Hill C, Ross RP (2008) The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol 69(1):218–230
Foulston LC, Bibb MJ (2010) Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Proc Natl Acad Sci USA 107:13461–13466
Foulston LC, Bibb MJ (2011) Feed-forward regulation of microbisporicin biosynthesis in Microbispora corallina. J Bacteriol 193:3064–3071
Ghobrial O, Derendorf H, Hillman JD (2010) Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci 99:2521–2528
Goto Y, Li B, Claesen J, Shi Y, Bibb MJ, van der Donk WA (2010) Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights. PLoS Biol 8:e1000339
Grasemann H, Stehling F, Widmann R, Laliberte TW, Molina L, Döring G, Ratjen F (2007) Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 131:1461–1466
Guder A, Schmitter T, Wiedemann I, Sahl HG, Bierbaum G (2002) Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity. Appl Env Microbiol 68:106–113
Helfrich M, Entian KD, Stein T (2007) Structure-function relationships of the lanthionine cyclase SpaC involved in biosynthesis of the Bacillus subtilis peptide antibiotic subtilin. Biochemistry 46:3224–3233
Hindré T, Le Pennec JP, Haras D, Dufour A (2004) Regulation of lantibiotic lacticin 481 production at the transcriptional level by acid pH. FEMS Microbiol Lett 231:291–298
Holtsmark I, Mantzilas D, EijsinkV GH, Brurberg MB (2006) Purification, characterization, and gene sequence of michiganin A, an actagardine-like lantibiotic produced by the tomato pathogen Clavibacter michiganensis subsp. michiganensis. Appl Environ Microbiol 72:5814–5821
Hsu SD, Breukink E, Tischenko E, Lutters MAG, de Kruijff B, Kaptein R, Bonvin MJJ, van Nuland NAJ (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nature Struc Mol Biol 11:963–967
Islam MR, Nishie M, Nagao J, Zendo T, Keller S, Nakayama J, Kohda D, Sahl HG, Sonomoto K (2012) Ring A of Nukacin ISK-1: a lipid II binding motif for type-A(II) lantibiotic. J Am Chem Soc 134:3687–3690
Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, Nakayama J, Sonomoto K (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. Mol Microbiol 72:1438–1447
Jabes D, Brunati C, Guglierame P and Donadio S (2009) In vitro antibacterial profile of the new lantibiotic NAI-107. 49th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, Abs F1- 1502
Jabes D, Brunati C, Candiani G, Riva S, Romanó G, Donadio S (2011) Efficacy of the new antibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. Antimicrob Agents Chemother 55:1671–1676
Kellner R, Jung G, Josten M, Kaletta C, Entian KD, Sahl HG (1989) Pep5: structure elucidation of a large lantibiotic. Angew Chemie Int Ed English 28(5):616–619
Kessler H, Steuernagel S, Gillessen D, Kamiyama T (1987) Complete sequence determination and localisation of one imino and three sulfide bridges of the nonadecapapetide Ro 09–0198 by homonuclear 2D–NMR spectroscopy. The DQF-relayed-NOESY-Experiment. Helv Chim Acta 70:726–741
Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M (2009) Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7)analog. J Pharmacol Exper Ther 328:849–854
Kupke T, Stevanovic S, Sahl HG, Gotz F (1992) Purification and characterization of EpiD, a flavoprotein involved in the biosynthesis of the lantibiotic epidermin. J Bacteriol 174:5354–5361
Li B, Yu JP, Brunzelle JS, Moll GN, van der Donk WA, Nair SK (2006) Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311:1464–1467
Li B, Sher D, Kelly L, Shi Y, Huang K, Knerr PJ, Joewono I, Rusch D, Chisholm SW, van der Donk WA (2010) Catalytic promiscuity in the biosynthesis of cyclic peptide secondary metabolites in planktonic marine cyanobacteria. Proc Natl Acad Sci U S A 107:10430–10435
Lubelski J, Rink R, Khusainova R, Moll GN, Kuipers OP (2008) Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 65:455–476
Majer F, Schmid DG, Altena K, Bierbaum G, Kupke T (2002) The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. J Bacteriol 184:1234–1243
Mattick ATR, Hirsch A (1947) Further observations on an inhibitory substance (Nisin) from lactic streptococci. Lancet 253(2):5–8
Marsh AJ, O’Sullivan O, Ross RP, Cotter PD, Hill C (2010) In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria. BMC Genomics 11:679
McAuliffe O, Ross RP, Hill C (2001) Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol Rev 25:285–308
McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc Natl Acad Sci USA 103:17243–17248
Okesli A, Cooper LE, Fogle EJ, van der Donk WA (2011) Nine post-translational modifications during the biosynthesis of cinnamycin. J Am Chem Soc 133(34):13753–13760
O′Sullivan DJ, Lee JH (2009) Lantibiotics and uses thereof. WO2009/058440
Paul M, Patton GC, van der Donk WA (2007) Mutants of the zinc ligands of lacticin 481 synthetase retain dehydration activity but have impaired cyclization activity. Biochemistry 46:6268–6276
Patton GC, Paul M, Cooper LE, Chatterjee C, van der Donk WA (2008) The importance of the leader sequence for directing lanthionine formation in lacticin 481. Biochemistry 47:7342–7351
Peschel A, Augustin J, Kupke T, Stevanovic S, Götz F (1993) Regulation of epidermin biosynthetic genes by EpiQ. Mol Microbiol 9:31–39
Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJM, Kuipers OP, Moll GN (2007) Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation. Appl Env Microbiol 73:5809–5816
Rogers LA, Whittier EO (1928) Limiting factors in the lactic fermentation. J Bacteriol 16:211–229
Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP, Hill C (1999) Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem 274:37544–37550
Sahl HG, Bierbaum G (1998) Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from Gram-positive bacteria. Ann Rev Microbiol 52:41–79
Schmitz S, Hoffmann A, Szekat C, Rudd B, Bierbaum G (2006) The lantibiotic mersacidin is an autoinducing peptide. Appl Env Microbiol 72:7270–7277
Skaugen M, Nissen–Meyer J, Jung G, Stevanovic S, Sletten K (1994) In vivo conversion of L–serine to d–alanine in a ribosomally synthesized polypeptide. J Biol Chem 269(44):27183–27185
Smith L, Hillman JD (2008) Therapeutic potential of type A(I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol 11:401–408
Wadman SN, Citron DM, Choi S, Cortes J, Goldstein EJC (2009) NVB302: in vitro activity against Clostridium difficile and intestinal strains of anaerobic bacteria. 49th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, abs F1- 1518
Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ, Bibb MJ (2003) Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM40005. Proc Natl Acad Sci USA 100:4316–4321
Xie L, Miller LM, Chaterjee C, Averin O, Kelleher NL, van der Donk WA (2004) Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science 303:679–681
You YO, van der Donk WA (2007) Mechanistic investigations of the dehydration reaction of lacticin 481synthetase using site directed mutagenesis. Biochemistry 46:5991–6000
Zimmermann N, Metzger JW, Jung G (1995) The tetracyclic lantibiotic actagardine 1H-NMR and 13C-NMR assignments and revised primary structure. Eur J Biochem 228:786–797
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Cortes, J. (2014). Lantibiotics and Similar Peptides Produced by and Active on Gram-Positives: Discovery, Development and Perspectives. In: Marinelli, F., Genilloud, O. (eds) Antimicrobials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39968-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-39968-8_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-39967-1
Online ISBN: 978-3-642-39968-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)